Anthem Biosciences Closes Trading Window Ahead of Q4 FY26 Results

Anthem Biosciences Limited will close its trading window for designated persons starting April 1, 2026. The closure will remain in effect until 48 hours after the board meeting to approve financial results for the quarter and year ending March 31, 2026.

Reader Takeaway: Trading window closure signals upcoming Q4 FY26 results; investors await company performance.

What's Happening Now

Anthem Biosciences Limited has announced the closure of its trading window for designated persons, effective April 1, 2026.

This restriction is standard practice and aims to prevent potential insider trading around the announcement of financial results.

The window will reopen 48 hours after the company's Board of Directors convenes to approve the financial statements for the quarter and full year ending March 31, 2026.

Why This Matters

Trading window closures are a regulatory requirement designed to ensure market integrity and fair disclosure of material information.

They prevent individuals with access to unpublished price-sensitive information from trading in the company's securities.

This move signals that the company is preparing to release its Q4 and full-year FY26 financial performance.

Background on Performance

Anthem Biosciences, a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO), recently reported its Q3 and nine months FY26 results.

While Q3 FY26 consolidated revenue saw a year-on-year decline of 15.0% to ₹423.2 crore, the nine-month period showed revenue growth of 11.2% to ₹1,513.4 crore.

The company's EBITDA margins improved to 41.8% in Q3 FY26, benefiting from backward integration and cost control. Anthem Biosciences guides for FY26 revenue growth of 15-16%.

The company's IPO was in July 2025, and it has been focused on expanding manufacturing capacity.

What Changes Now

Designated persons within Anthem Biosciences are prohibited from buying or selling company securities during the trading window closure.

All attention will now shift to the upcoming board meeting and the subsequent announcement of the financial results.

Past Trading Violations

Anthem Biosciences has faced past instances of insider trading code violations by designated employees. In October and November 2025, the company disclosed that certain individuals had traded securities during trading window closures or without prior approval, leading to warning letters being issued.

These recurring issues highlight a potential concern regarding adherence to trading regulations among key personnel.

Industry Peers

Anthem Biosciences operates in the competitive CRDMO and pharmaceutical services sector. Key peers in India include Syngene International, Sai Life Sciences, and Aragen Life Sciences, which also offer integrated drug discovery and manufacturing solutions.

Key Dates

• Trading window closure begins: April 1, 2026.
• Financial results period: Quarter and Year ending March 31, 2026.

What to Watch For Next

• The official announcement date of the Board Meeting to approve Q4 and FY26 financial results.
• The release of the audited financial results for Q4 and FY26.
• Management commentary on the full-year performance and outlook for FY27 during the post-results disclosure.
• Any updates on the company's capacity expansion projects, such as Unit-4.
• Investor reaction to the financial performance and any forward-looking guidance provided.
• Any further developments regarding compliance with trading window rules and SEBI regulations.